As representative of ICIs, the Food and Drug Administration has approved treatment with anti-PD-1 and anti-PD-L1 monoclonal antibodies for metastatic triple negative breast cancer (TNbreast cancer) immunotherapy. This evidence concerns the gene PDCD1 and triple-negative breast carcinoma.